Amylyx Pharmaceuticals (AMLX) Financials

$32.10

$-0.30 (-0.93%)

As on 10-Sep-2026 16:00EDT

Market cap

$3,800 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

15.8

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	--	--	87.37	380.79	22.23	0.29
Cost of Revenue	20.06	0.53	42.16	25.44	2.99	0.05
Gross Profit	-20.06	-0.53	45.22	355.35	19.24	0.29
Operating Expenses	142.14	152.77	359.95	316.54	220.58	82.69
Operating Profit (EBIT)	-162.10	-153.29	-314.73	38.80	-201.34	-82.69
Other Income	--	--	--	--	3.74	--
Profit before Tax	-152.05	-144.69	-302.14	54.30	-197.60	-87.93
Provision for Tax	0.05	0.05	-0.39	5.03	0.77	-0.05
Profit after Tax (Net Income)	-152.09	-144.74	-301.74	49.27	-198.38	-87.88
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-198.38	-87.93

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	239.17	305.26	164.77	433.43	340.61	-151.17
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	4.25	4.70	0.46	1.98	4.24	239.39
Current Liabilities	21.15	22.69	28.41	82.04	46.61	17.40
Total Liabilities	285.71	332.65	193.63	517.45	391.45	105.61

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	8.23	8.97	4.20	52.79	9.32	0.66
Current Assets	256.34	323.67	189.43	464.67	382.13	104.95
Total Assets	285.71	332.65	193.63	517.45	391.45	105.61
Total Debt*	5.26	5.96	1.98	4.24	6.28	--
Net Current Assets	235.19	300.98	161.03	382.62	335.52	87.56

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-123.34	-167.65	11.92	-179.87	-74.80
Cash Flow from Investing Activities	--	14.04	75.65	92.05	-238.99	-46.41
Cash from Financing Activities	--	257.03	0.35	3.54	431.79	158.51
Net Cash Inflow / Outflow	--	--	--	--	12.93	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-1.48	-1.53	-4.40	0.71	-3.03	-1.59
Cash EPS ($)	--	-1.52	-4.39	0.73	-3.03	-1.59
Adjusted Book Value ($)	--	3.23	2.40	6.26	5.21	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-1.30	-2.44	0.17	-2.75	-1.35
Free Cash Flow per Share ($)	--	-1.31	-2.45	0.15	-2.79	-1.36

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-60.56	-99.85	12.56	-202.72	81.19
ROE (%)	-55.87	-61.59	-100.88	12.73	-209.43	80.66
ROA (%)	-60.63	-55.00	-84.87	10.84	-79.82	-146.81
EBIT Margin (%)	--	--	-334.07	14.26	-905.72	-29,013.33
Net Margin (%)	--	--	-345.36	12.94	-763.86	-30,834.74
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	--	-1.00	-0.77	16.13	77.00	-0.56
EBIT Growth (%)	20.23	50.43	-637.56	126.97	-143.49	-111.99
Net Profit Growth (%)	18.93	52.03	-712.42	124.84	-125.74	-107.85
EPS Growth (%)	40.73	0.65	-7.18	1.23	-0.91	-0.73
Book Value Growth (%)	14.20	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-7.89	-0.86	20.67	-12.18	--
Price / Book Value	15.76	3.74	1.57	2.35	7.10	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-11.71	-5.77	-0.29	11.76	-10.34	--
Close Price ($)	17.96	12.08	3.78	14.72	36.95	--
High Price ($)	19.15	16.96	19.95	41.93	39.78	--
Low Price ($)	5.97	2.60	1.58	11.82	6.51	--
Market Cap ($ Cr)	3,799.53	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	0.02	0.01	0.01	0.02	--
Short term debt to equity ratio	0.00	0.00	0.01	0.01	0.01	--
Current Ratio	12.12	14.27	6.67	5.66	8.20	6.03
Quick Ratio	12.12	--	6.67	5.20	7.99	6.03
Interest Coverage	--	--	--	--	-46.92	-2,296.89

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	--	0.51	10.52	68.85	--
Asset Turnover	--	--	0.25	0.84	0.09	0.00
Receivable days	--	--	84.65	26.55	125.74	--
Inventory Days	--	--	166.02	345.22	596.08	--
Payable days	--	2,246.46	108.30	203.28	648.55	28,043.47
Cash Conversion Cycle	--	--	142.36	168.49	73.27	-28,043.47

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.